KeyCorp Issues Positive Forecast for ICU Medical (NASDAQ:ICUI) Stock Price

Key Points

• KeyCorp raised its price target for ICU Medical to $189 from $187 and maintained an Overweight rating, implying about 8.1% upside from the prior close. Analysts’ consensus rating is Moderate Buy, with an average target of $195.20.
• ICU Medical beat third-quarter estimates, posting earnings of $2.44 per share versus $2.14 expected and revenue of $556.22 million versus $552.03 million expected; revenue grew 4.4% year over year. The company reaffirmed its fiscal 2026 guidance and expects results near the high end of its range.
• Company insiders sold a combined 21,830 shares worth about $3.9 million over the last quarter.

ICU Medical (NASDAQ:ICUI - Get Free Report) had its price objective hoisted by analysts at KeyCorp from $187.00 to $189.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an "overweight" rating on the medical instruments supplier's stock. KeyCorp's price objective would indicate a potential upside of 8.10% from the stock's previous close.

A number of other brokerages have also recently issued reports on ICUI. Weiss Ratings raised ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Zacks Research cut ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $195.20.

ICU Medical Trading Up 4.3%

NASDAQ:ICUI opened at $174.84 on Friday. The company has a market cap of $4.37 billion, a P/E ratio of 146.95, a P/E/G ratio of 2.17 and a beta of 0.88. The stock's fifty day moving average price is $162.97 and its two-hundred day moving average price is $149.18. ICU Medical has a 1 year low of $113.37 and a 1 year high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.30. The firm had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the company earned $2.03 earnings per share. As a group, analysts expect that ICU Medical will post 7.22 EPS for the current year.

Insider Buying and Selling at ICU Medical

In other news, Director Elisha W. Finney sold 378 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director owned 4,871 shares of the company's stock, valued at $888,860.08. This represents a 7.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Virginia Sanzone sold 4,856 shares of the firm's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the sale, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. This trade represents a 24.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,830 shares of company stock valued at $3,905,003 over the last quarter. Company insiders own 2.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ICUI. Gagnon Securities LLC lifted its stake in ICU Medical by 0.8% in the third quarter. Gagnon Securities LLC now owns 29,630 shares of the medical instruments supplier's stock worth $4,756,000 after purchasing an additional 230 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in ICU Medical by 52.7% during the third quarter. Maryland State Retirement & Pension System now owns 5,549 shares of the medical instruments supplier's stock valued at $891,000 after buying an additional 1,914 shares during the period. Jefferies Financial Group Inc. purchased a new stake in ICU Medical during the third quarter valued at about $987,000. Illinois Municipal Retirement Fund grew its stake in shares of ICU Medical by 9.2% during the third quarter. Illinois Municipal Retirement Fund now owns 13,788 shares of the medical instruments supplier's stock valued at $2,213,000 after buying an additional 1,162 shares during the last quarter. Finally, Lido Advisors LLC grew its stake in shares of ICU Medical by 15.4% during the third quarter. Lido Advisors LLC now owns 3,707 shares of the medical instruments supplier's stock valued at $595,000 after buying an additional 494 shares during the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical reported third-quarter earnings of $2.44 per share, above the $2.14 consensus estimate and up from $2.03 a year earlier. Revenue was $556.22 million, also ahead of expectations, and increased 4.4% year over year. ICU Medical Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reaffirmed fiscal 2026 guidance and said it expects results toward the high end of its previously provided range, signaling confidence in its outlook. ICU Medical Announces Q3 Results and Reaffirms Guidance
• Neutral Sentiment: Despite the earnings beat and reaffirmed guidance, the stock is lower. The articles provided do not point to a clear company-specific reason for the move. ICU Medical Q3 Adjusted Earnings, Revenue Rise

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.